#USA #New York #Securities Fraud #Pomerantz Law Firm #Agios Pharmaceuticals

Pomerantz Law Firm Investigates Agios Pharmaceuticals

Pomerantz LLP, a leading law firm with a focus on class action litigation, has officially begun an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) on behalf of its investors. The investigation is centered around potential claims that Agios and some of its executive officers may have engaged in securities fraud or other illegal business practices.

This announcement follows a press release from Agios on September 4, 2025, where the company disclosed that the U.S. Food and Drug Administration (FDA) has delayed its decision regarding the supplemental New Drug Application (sNDA) for its drug PYRUKYND® (mitapivat). This oral pyruvate kinase activator is designed for treating adults with non-transfusion-dependent and transfusion-dependent forms of alpha- or beta-thalassemia. The FDA extended the decision deadline by three months to December 7, 2025, prompting significant investor concern.

As a result of this news, Agios's stock experienced a sharp decline, plummeting by $4.48 per share, which represents an 11.03% drop, ultimately closing at $36.13 per share. This sudden fall in stock price has raised red flags among investors, indicating potential mismanagement or misleading information regarding the company's operations and FDA interactions.

Pomerantz LLP is reaching out to investors affected by Agios's performance to gather information regarding their experiences and evaluate legal avenues that can be pursued. Investors who have suffered losses in their investment in Agios Pharmaceuticals are encouraged to contact the firm for assistance. Danielle Peyton, a representative at Pomerantz, is available for inquiries and can be reached at [email protected] or by calling 646-581-9980, ext. 7980.

Pomerantz LLP, renowned for its prowess in corporate, securities, and antitrust class litigation, was established by Abraham L. Pomerantz, who is often referred to as the dean of the class action bar. Now, over 80 years after its founding, the firm remains committed to advocating for the rights of investors who have been victims of securities fraud, breaches of fiduciary duties, and corporate misconduct. The firm has a successful history of recovering substantial damages for class members, reinforcing its reputation as a powerhouse in the field of securities litigation.

In summary, the ongoing investigation highlights not only the concerns surrounding Agios Pharmaceuticals and its leadership but also underscores the increasing vigilance of legal entities like Pomerantz LLP in protecting investors' rights in the constantly evolving landscape of pharmaceutical investments. If you believe you have been impacted by Agios's market activities, now is the time to engage with legal representation to explore your options.

For more information about the ongoing proceedings or to join in any possible legal actions, it is crucial for affected investors to stay informed and connected with Pomerantz LLP. The implications of this investigation may have long-lasting effects on the company and its stakeholders as efforts to address potential securities violations develop further.